Clinical Trial Update: More Patients Added to Medicus Pharma’s Phase 2 Study of D-MNA for BCC
The Institutional Review Board (IRB) has approved an increase in number of patients to be included in Medicus Pharma’s Phase 2 clinical study of D-MNA for the Treatment of Nodular Basal Cell Carcinoma (BCC).